The 5-year cumulative incidence rate of HCC was 17.6% in patients with normalized on-treatment ALT and 16.8% in patients with elevated on-treatment ALT (p = 0.39) (Fig. 1b). This evidence concerns the gene GPT and hepatocellular carcinoma.